Moderna: three new vaccine programs thanks to the ARNm

(CercleFinance.com) - Moderna today announced the extension of its innovative vaccine portfolio with the development of three new programs.


Following the clinical success of its Covid-19 vaccine based on the mRNA (mRNA) technique, Moderna announced that it is working on several candidate vaccines based on the same technology: vaccines against seasonal influenza, HIV and the Nipah virus.

Moderna has also announced an extension of its respiratory syncytial virus (RSV) vaccination program for the elderly.

In addition, beyond vaccines, we are extending our mRNA development work to a total of 24 programs in five therapeutic areas, it said.


Copyright (c) 2021 CercleFinance.com. All rights reserved.